Zachary Il'giovine
Advanced Heart Failure and Transplant Cardiology · Nashville, TNNPI 1427444272
Payments from drug & device makers
What this record shows
Abbott accounts for 68.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $4,164 and has fallen 80.4% since, to $817 in 2025.
Across 71 payments — averaging $77.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Abiomed$1K
- Pfizer$206
- Irhythm Technologies, Inc.$155
- E.r. Squibb & Sons, L.L.C.$148
- Novo Nordisk$64
- plus $100 from 5 others
Across 1 payment — averaging $211.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$211
What the payments were for
- Travel & lodging$2,40944%
- Food & beverage$3,11756%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $3,803 |
| Abiomed | 10 | $1,049 |
| Pfizer | 11 | $206 |
| Irhythm Technologies, Inc. | 1 | $155 |
| E.r. Squibb & Sons, L.L.C. | 6 | $148 |
| Novo Nordisk | 3 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| AstraZeneca | 1 | $16 |
| Medtronic | 1 | $15 |
| Amgen | 1 | $14 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,151
- Impella$695
- ZIO XT Patch$155
- Zio monitor$155
How this compares
$5,526 in reported general payments places this provider in the 60th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
See all advanced heart failure and transplant cardiology providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 149 | $116,209 |
| FarxigaDapagliflozin Propanediol | 103 | $72,404 |
| JardianceEmpagliflozin | 56 | $45,532 |
| Valsartan | 33 | $1,508 |
| Spironolactone | 157 | $892 |
| Metoprolol Succinate | 71 | $666 |
| Torsemide | 34 | $583 |
| Carvedilol | 45 | $274 |
| Furosemide | 40 | $155 |
| Atorvastatin Calcium | 27 | $147 |
| ClopidogrelClopidogrel Bisulfate | 15 | $130 |
| Losartan Potassium | 17 | $84 |
| Amlodipine Besylate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $16 | $72,404103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.
Other advanced heart failure and transplant cardiology in Nashville
- Jonathan MenachemNashville$79K
- Richa GuptaNashville$46K
- Matthew DeshazoNashville$38K
- Lynne StevensonNashville$25K
- Warren StriblingNashville$23K
- Mark AaronNashville$13K
- John BiglaneNashville$9K
- Jeremy BrooksbankNashville$9K
- Ashley BockNashville$8K
- Andrew McRaeNashville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.